Approximately three quarters of all patients with NMOSD test positive for anti-AQP4 auto-antibodies.
The FDA approved Soliris following an expedited six-month priority review. NMOSD is a rare, severe autoimmune disease that attacks the central nervous system without warning.
These attacks, also referred to as relapses, can cause progressive and irreversible damage to the brain, optic nerve and spinal cord, which may lead to long-term disability.
Complement activation due to anti-AQP4 antibodies is one of the primary underlying causes of the destruction in these patients.
In the PREVENT trial, Soliris, a first-in-class complement inhibitor, demonstrated safety and efficacy and met its primary endpoint of prolonging the time to first adjudicated relapse and reducing the risk of relapse.
NMOSD disproportionately strikes young women in the prime of their lives, with the average age of first onset at just 39 years.
Race is also a significant risk factor for disability and mortality in NMOSD.
In the US, African Americans are over-represented among patients diagnosed with NMOSD and more likely to suffer more frequent and more severe attacks.
Previously known as Devic's Disease, NMOSD is often confused with other neurological illnesses such as multiple sclerosis, which can lead to delays in diagnosis and treatment with medicines that can worsen disease progression.
This approval is based on comprehensive results from the Phase 3 randomised, double-blind placebo controlled PREVENT trial, which were recently published in The New England Journal of Medicine.
In the study, patients with NMOSD who were anti-AQP4 antibody positive were treated with SOLIRIS or placebo.
At 48 weeks, 98 % of patients treated with SOLIRIS were relapse free compared to 63 % of patients receiving placebo.
This effect was observed through 144 weeks of treatment, with 96% of patients treated with SOLIRIS relapse free compared to 45 % of patients in the placebo arm. Soliris-treated patients experienced similar improvement in time to first adjudicated on-trial relapse with or without concomitant treatment.
Of the patients treated solely with Soliris, without receiving other immunosuppressive therapies,, 100% were relapse free at 144 weeks compared to 20% in the placebo group.
The safety profile of Soliris was consistent with that seen for Soliris in other clinical studies. The most common adverse events observed in the PREVENT study were upper respiratory tract infection (29% of patients in the Soliris group vs. 13% in the placebo group), nasopharyngitis (21 vs. 19%), diarrhea (16 vs. 15%), back pain (15 vs. 13%) and dizziness (15 vs. 13%).
The serious adverse events that were reported for more than one patient in either group were pneumonia (three patients in the Soliris group vs. one patient in the placebo group) and cellulitis, sepsis and urinary tract infection (two patients for each event in the Soliris group vs. no patient in the placebo group).
One patient receiving Soliris and concomitant supportive IST died from infectious pleural effusion.
The patient had an extensive history of pulmonary disease and was an active smoker.
No cases of meningococcal infection were observed in the study.
The European Medicines Agency and the Japanese Ministry of Health, Labour and Welfare are reviewing Alexion's applications to add the treatment of NMOSD to the marketing authorisations for Soliris in the European Union and Japan, respectively.
Soliris has received Orphan Drug Designation for the treatment of patients with NMOSD in the US, EU and Japan.
Soliris is a prescription medicine called a monoclonal antibody. Soliris is used to treat patients with a disease called Paroxysmal Nocturnal Hemoglobinuria. Soliris is used to treat adults and children with a disease called atypical Hemolytic Uremic Syndrome.
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer
Oxford Biomedica to acquire ABL Europe
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
SK bioscience signs development licensing agreement with Hilleman Laboratories
Poolbeg Pharma expands patent portfolio with Immunomodulator II approval in Japan
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation